Table 1.
Baseline characteristics of all the studied groups.
| HCC (n = 308) | LC (n = 60) | BLD (n = 60) | P value | |
|---|---|---|---|---|
| Age (years) | 51.4 ± 12.2 | 46.6 ± 10.3 | 42.53 ± 12.3 | P < 0.001 |
| Gender (male/female) | 271/37 | 48/12 | 46/14 | P = 0.014 |
| Total bilirubin (mg/dl) | 16.64 ± 9.81 | 10.87 ± 3.85 | 7.96 ± 2.31 | P = 0.026 |
| AFP (ng/ml) | 235.30 (0.70-121000.00) | 13.16 (1.46-56.50) | 4.99 (0.60-45.78) | P < 0.001 |
| PIVKA-II (mAU/ml) | 1805.50 (9.00-75000.00) | 24.00 (11.00-45.00) | 25.00 (12.00-46.00) | P < 0.001 |
| AST (U/L) | 49.70 (11.80-938.90) | 55.60 (11.00-298.00) | 18.80 (12.50-39.6) | P = 0.034 |
| ALT (U/L) | 40.40 (8.6-1265.7) | 38.10 (4.00-158.50) | 15.85 (3.20-45.30) | P = 0.029 |
| ALB (g/L) | 39.20 (27.70-52.50) | 40.55 (23.90-50.20) | 51.20 (33.40-69.20) | P = 0.076 |
| PT-INR | 1.47 (0.75-1.62) | 1.55 (0.75-1.94) | 1.89 (0.95-2.44) | P = 0.130 |
Data are the mean ± standard deviation or median (minimum-maximum) values. HCC: hepatocellular carcinoma; LC: liver cirrhosis; BLD: benign liver disease; AFP: alpha-fetoprotein; PIVKA-II: prothrombin induced by vitamin K absence II; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ALB: albumin; PT-INR: prothrombin time-international normalized ratio.